Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports.
Little is known about factors contributing to disease-evolution in early-phase myelodysplastic syndromes (MDS). In this article, low erythropoietin (EPO) production is discussed as a 'non-oncogenic' co-factor responsible for disease-manifestation in a group of patients with low-risk MDS. The hypothesis is based on the observations that (i) individuals with bone marrow dysplasia and MDS-related karyotypes but relatively high EPO levels may present without anemia and thus without frank MDS over years, (ii) several elderly patients with idiopathic anemia are low EPO producers and their anemia can be corrected with EPO therapy, and (iii) the well-known fact that low-risk MDS patients typically respond to EPO therapy when they have low endogenous EPO levels.
Valent
Peter
P
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. peter.valent@meduniwien.ac.at
D000368:Aged; D000369:Aged, 80 and over; D002872:Chromosome Deletion; D002894:Chromosomes, Human, Pair 4 / Q000235:genetics; D004921:Erythropoietin / Q000097:blood* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007621:Karyotyping; D008297:Male; D009190:Myelodysplastic Syndromes / Q000097:blood* / Q000188:drug therapy / Q000235:genetics; D011379:Prognosis; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin